Status:
TERMINATED
Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma
Lead Sponsor:
University of Chicago
Conditions:
Metastatic Renal Cell Carcinoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer ...
Detailed Description
Renal cell carcinoma is a chemotherapy and radiotherapy resistant neoplasm that has a poor prognosis. Immunotherapy with the biologic agent IL-2 consistently produces a response rate of 10-15 %. Curre...
Eligibility Criteria
Inclusion
- Patients must express HLA-A2
- Patients must have histologically or cytologically proven renal cell carcinoma that expresses G250 by IHC
- Patients must have completely resected disease without any evidence of residual local or metastatic disease
- Patients with resected locally advanced disease
- Patients with metastatic disease(including synchronous metastatic site)
- Patients with solitary metachronous metastatic disease
- Age \>/=18 years
- ECOG performance status 0-1
- Patients must have normal organ and marrow function
- Ability to understand and the willingness to sign a written informed consent document
Exclusion
- Patients who have had chemotherapy, radiotherapy, or an experimental (investigational) agent prior to starting treatment. Prior biologic therapy (IL-2 or interferon) is allowed only if it precedes a curative surgical therapy.
- Patients may not have received a previous G250 vaccine.
- Patients with residual metastatic disease following surgical resection are excluded from this clinical trial.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to G250, Montanide ISA-5 1, OM-CSF, or IL-2.
- Patients must not have autoimmune disorders (SLE, Rheumatoid Arthritis), conditions of immunosuppression (such as HIV), or treatment with immunosuppressive drugs (including oral steroids, continuous use of topical steroids, steroid inhalers). Replacement doses of steroids for patients with adrenal insufficiency are allowed.
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, active GI bleeding, inflammatory bowel disease or psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnant or breast-feeding women
- HIV-positive patients
- Patients with a currently active second malignancy other than non-melanoma skin cancer or carcinoma in situ of the cervix are not to be registered.
Key Trial Info
Start Date :
October 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2007
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00203866
Start Date
October 1 2003
End Date
March 1 2007
Last Update
September 5 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Chicago
Chicago, Illinois, United States, 60637